Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 14/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22926103 | 0.88 | CHEK1 (0.38) | DGAT1CHEK1 | |
| SCHEMBL29620922 | 0.88 | CHEK1 (0.38) | DGAT1CHEK1 | |
| SCHEMBL22925913 | 0.77 | HDAC6 (0.43) | DGAT1CHEK1 | |
| SCHEMBL29620964 | 0.77 | HSD11B1 (0.45) | DGAT1CHEK1 | |
| SCHEMBL24636908 | 0.77 | HSD11B1 (0.45) | DGAT1CHEK1 | |
| SCHEMBL22925623 | 0.76 | ACR (0.40) | CYP3A4CYP2C19CSGALNACT1CDK2AKT1 | |
| SCHEMBL28733616 | 0.76 | ACR (0.40) | CYP3A4CYP2C19CSGALNACT1CDK2AKT1 | |
| SCHEMBL22926105 | 0.76 | LRRK2 (0.40) | DGAT1CHEK1 | |
| SCHEMBL22925496 | 0.74 | TRPV1 (0.47) | CHEK1 | |
| SCHEMBL29620971 | 0.74 | GSK3B (0.62) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | DGAT1 164/4885CHEK1 1509/4885CYP3A4 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.